Protocol Ledger

NCT03977155 · Phase II · COMPLETED

Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)

Interventional Phase II clinical trial protocol NCT03977155 sponsored by Boston Pharmaceuticals in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-06-04 Enrollment: 133 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03977155
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)133 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03977155
Protocol FieldVerified Registry Value
NCT IdentifierNCT03977155
Consolidated Lead SponsorBoston Pharmaceuticals
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment133 participants (ACTUAL)
Registered Start Date2019-06-04
WhyStopped ClassificationNot Stopped

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI